Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel

Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune in the last year for NDAs with priority review status, the consulting firm Parexel concludes in a new report.